Core Viewpoint - NCR Voyix (VYX) shares have increased by 6.2% over the past four weeks, closing at $11.56, with a mean price target of $14.63 indicating a potential upside of 26.6% [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.33, where the lowest estimate is $11 (4.8% decline) and the highest is $18 (55.7% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 7.1% over the past month, with one estimate increasing and no negative revisions [12] Zacks Rank and Investment Potential - VYX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [13]

Core Viewpoint - Instil Bio, Inc. (TIL) has shown significant stock price appreciation of 134% over the past four weeks, with analysts projecting a mean price target of $118.67, indicating a potential upside of 246.7% from the current price of $34.23 [1] Price Targets and Analyst Consensus - The average price target for TIL ranges from a low of $51 to a high of $180, with a standard deviation of $64.73, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 49% increase, while the highest suggests a 425.9% upside, highlighting the potential for significant price movement [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about TIL's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - Over the past 30 days, one earnings estimate has increased, leading to a 7.2% rise in the Zacks Consensus Estimate for the current year [12] - TIL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Core Viewpoint - American Superconductor (AMSC) shares have increased by 24.3% in the past four weeks, closing at $29.23, with a mean price target of $39 indicating a potential upside of 33.4% [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $1, where the lowest estimate of $38 suggests a 30% increase, and the highest estimate of $40 indicates a 36.9% increase from the current price [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about AMSC's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [9] - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with two estimates increasing and no negative revisions [10] Zacks Rank and Investment Potential - AMSC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [11]

Core Viewpoint - QXO, Inc. shows significant potential for upside, with a mean price target of $34.33 indicating a 70.8% increase from the current trading price of $20.10, which has already gained 23.5% over the past four weeks [1]. Price Targets and Analyst Consensus - The average price target for QXO ranges from a low of $27 to a high of $44, with a standard deviation of $8.74, suggesting variability in analyst estimates. The lowest estimate indicates a 34.3% increase, while the highest suggests an 118.9% upside [2]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding QXO's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. This trend has a strong correlation with near-term stock price movements [11]. - Over the last 30 days, one earnings estimate for QXO has increased, leading to a Zacks Consensus Estimate rise of 391.7% [12]. Zacks Rank and Investment Potential - QXO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13].

Group 1 - DigitalBridge (DBRG) shares have increased by 11.8% over the past four weeks, closing at $10.63, with a mean price target of $16.65 indicating a potential upside of 56.6% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $2.71, where the lowest estimate is $10.50 (1.2% decline) and the highest is $20 (88.2% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 26.9% over the past month [11][12] Group 2 - The Zacks Rank for DBRG is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets are often viewed as a key metric, they can mislead investors, and analysts may set overly optimistic targets due to business incentives [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9]

Core Viewpoint - Immunome, Inc. (IMNM) has seen a 19.1% increase in share price over the past four weeks, closing at $9.49, with analysts projecting a potential upside of 158.2% based on a mean price target of $24.50 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.76, indicating variability among analysts [2]. - The lowest price target of $20 suggests an 110.8% increase, while the highest target of $38 indicates a potential surge of 300.4% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, four estimates have been revised upward, leading to a 14.8% increase in the Zacks Consensus Estimate for the current year [12]. - IMNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].

Group 1 - Shares of Quanex Building Products (NX) have increased by 7.5% over the past four weeks, closing at $20.19, with a mean price target of $37 indicating a potential upside of 83.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $31 suggests a 53.5% increase, and the highest estimate of $42 indicates a potential surge of 108% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 2.8% over the past month [11][12] Group 2 - NX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - Despite skepticism around the reliability of price targets, the direction implied by them appears to be a useful guide for potential price movements [10]

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 32.9% increase from the current price of $27.60 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30 to a high of $42, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 8.7% increase, while the highest suggests a 52.2% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment - Analysts exhibit strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 0.1% over the past month, with no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets due to business incentives [8][10] - Empirical research indicates that price targets rarely predict actual stock price movements, suggesting a need for skepticism [7][10]

Core Viewpoint - Veris Residential (VRE) shares have shown a slight increase of 0.2% over the past four weeks, closing at $15.33, with a potential upside of 25.9% based on Wall Street analysts' mean price target of $19.30 [1][11]. Price Targets and Analyst Estimates - The mean estimate for VRE comprises five short-term price targets with a standard deviation of $4.02, indicating variability among analysts; the lowest estimate suggests a 4.4% increase to $16, while the highest predicts a surge of 69.6% to $26 [2][9]. - Analysts have recently shown increasing optimism regarding VRE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with two estimates increasing and no negative revisions [12]. Analyst Behavior and Price Target Reliability - There is skepticism regarding the reliability of analysts' price targets, as empirical research indicates that these targets often mislead investors rather than provide accurate guidance [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations for stocks they cover [8]. - A low standard deviation in price targets suggests a high degree of agreement among analysts about the stock's price direction, serving as a starting point for further research [9]. Investment Ranking - VRE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13].

Core Viewpoint - Glaukos (GKOS) shows potential for significant upside, with a mean price target of $128.54 indicating a 34.4% increase from the current price of $95.64, supported by positive earnings estimate revisions [1][11]. Price Targets - The average of 13 short-term price targets ranges from a low of $72 to a high of $182, with a standard deviation of $33.39, indicating variability in analyst estimates [2]. - The lowest estimate suggests a decline of 24.7%, while the most optimistic estimate indicates a potential upside of 90.3% [2]. Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - The Zacks Consensus Estimate for the current year has increased by 11.8%, with four estimates moving higher and no negative revisions [12]. Zacks Rank - GKOS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets influenced by business relationships [3][8][10].